Therapies
Longevity drugs and therapies compared on outcome trials — GLP-1 agonists, metformin, rapamycin and the rest.
Topic overview →Weight-loss peptides compared: semaglutide, tirzepatide, retatrutide and CagriSema ranked by evidence
By weight-loss magnitude in published trials, the order is retatrutide (up to ~30.3% in TRIUMPH-1) ahead of tirzepatide (~20–22%, the strongest approved option) and CagriSema (~20.4% in REDEFINE-1), ahead of semaglutide (~15%) and liraglutide (~5–8%). But magnitude isn't the whole answer: retatrutide and CagriSema are not FDA-approved — retatrutide's Lilly is not expected to file until Q1 2027, with approval unlikely before late 2027 or 2028, and Novo Nordisk's CagriSema NDA was only submitted in December 2025. Today, tirzepatide is the strongest drug you can actually be prescribed.
PharmD-reviewed · Updated
Mounjaro vs Ozempic: which works better, and what it costs you
For weight loss, tirzepatide (Mounjaro, Zepbound) outperforms semaglutide (Ozempic, Wegovy) across every direct comparison published so far — but the evidence is weaker than the headlines imply, and the difference matters less than whether you can tolerate the drug, afford it long term, and stay on it.
PharmD-reviewed · Updated
The Longevity Brief
One evidence-graded email a week: what is new in longevity research, what is hype, and the one change actually worth making.
Free · one email a week · unsubscribe anytime.